Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Improved IDFS for breast cancer patients who received trastuzumab emtansine

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 1032
Rating:

Prof Charles Geyer - Allegheny General Hospital, Pittsburgh, USA

Prof Charles Geyer speaks to ecancer at SABCS 2018 about the results of the phase III KATHERINE clinical trial.

He explains that the trial was designed to improve the improved invasive disease-free survival (IDFS) of HER2-positive early breast cancer patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab.

Prof Geyer reports that substituting trastuzumab emtansine for adjuvant trastuzumab improved IDFS in patients with HER2-positive early breast cancer.

Watch his press conference here.

Read more about this work here

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation